Cell culture studies demonstrate that GLP3 exhibits differential potency across its three target receptors: it is approximately 8.9-fold more potent at the human GIP receptor (EC50: 0.0643 nM) compared to the endogenous GIP ligand, while showing reduced potency at GLP-1 receptors (0.4-fold, EC50: 0.775 nM) and glucagon receptors (0.3-fold, EC50: 5.79 nM) relative to their native hormones[3]
Image: Galina Zhigalova/Getty Images About the Author Maureen Salamon, Executive Editor, Harvard Women's Health Watch About the Reviewer Meghan Salamon, MS, RDN, LDN, CPT, Contributor Disclaimer: As a service to our readers, Harvard Health Publishing provides access to our library of archived content
Seven additional Phase 3 trials are expected to complete in 2026
This multi-receptor approach is intended to deliver greater weight loss and metabolic benefits than treatments targeting only one or two receptors
[DOI] [PMC free article] [PubMed] [Google Scholar] [41].Tran KT, Gavitt TD, Le TT, Graichen A, Lin F, Liu Y, Tulman ER, Szczepanek SM, Nguyen TD, A SingleAdministration Microneedle Skin Patch for MultiBurst Release of Vaccine against SARSCoV2, Advanced Materials Technologies 8(3) (2023) 2200905
It is water-extracted and minimally processed, providing a 'clean, naturally sourced, and transparent caffeine option
